Stock NLSP NLS PHARMACEUTICS AG
Add to a list
To use this feature you must be a member
Log inSign up

NLS Pharmaceutics AG

Equities

NLSP

CH0523961370

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-27 EDT 		After market 18:30:10
0.24 USD +31.43% Intraday chart for NLS Pharmaceutics AG 0.219 -8.75%
06-27 Sector Update: Health Care Stocks Slipping Late Afternoon MT
06-27 Sector Update: Health Care MT
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In

Latest news about NLS Pharmaceutics AG

Sector Update: Health Care Stocks Slipping Late Afternoon MT
Sector Update: Health Care MT
Top Midday Gainers MT
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk MT
NLS Pharmaceutics Reports Preclinical Data for Potential Parkinson's Disease Treatments; Shares Jump MT
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data MT
NLS Pharmaceutics AG Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists CI
NLS Pharmaceutics Says New Patent Application for Dual Non-Sulfonamide Orexin Receptor Agonists Published by WIPO MT
NLS Pharmaceutics Ltd. Enters into Additional Bridge Loan Addendums, or the Second Bridge Loan Addendums CI
NLS Pharmaceutics AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nls Pharmaceutics Ltd. Announces Resignation of Anthony S. Walsh as A Member of the Board of Directors CI
NLS Pharmaceutics Ltd. announced that it has received $1.75 million in funding CI
NLS Pharmaceutics Ltd. announced that it expects to receive $1.75 million in funding CI
NLS Pharmaceutics Files Plan to Regain Nasdaq Listing Compliance MT
NLS Pharmaceutics AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Top Midday Gainers MT
NLS Pharmaceutics Signs Option Agreement to Acquire Rights to Aexon Labs' Assets; Shares Rise MT
NLS Pharmaceutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value CI
Maxim Downgrades NLS Pharmaceutics to Hold From Buy MT
Top Premarket Gainers MT
NLS Pharmaceutics Ltd. cancelled the transaction announced on August 19, 2022 CI
Sector Update: Health Care Stocks Steady Pre-Bell Monday MT
NLS Pharmaceutics' Mazindol ER Trial to Move to Phase 3 MT

Chart NLS Pharmaceutics AG

Chart NLS Pharmaceutics AG
More charts

Company Profile

NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NLS PHARMACEUTICS AG Stock NLS Pharmaceutics AG
-59.32% 7.33M
MODERNA, INC. Stock Moderna, Inc.
+21.85% 46.93B
LONZA GROUP AG Stock Lonza Group AG
+37.63% 39.08B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.05% 38.48B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.04% 31.01B
CELLTRION, INC. Stock Celltrion, Inc.
-13.75% 26.14B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.65% 25.88B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+38.43% 12.53B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.92% 11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.29% 10.65B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NLSP Stock
  4. News NLS Pharmaceutics AG
  5. NLS Pharmaceutics Gets Hong Kong Patent for Mazindol to Treat Attention Deficit Hyperactivity Disorder